Re-expression of ER in Triple Negative Breast Cancers

NCT01194908 | Terminated Phase 1 Results DMC

• 2 other identifiers: IRB00029718WCI1696-09
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2). This means that agents such as trastuzumab (Herceptin®) and tamoxifen are not currently treatment options for their cancer. Another option for treating the patient's cancer at this point is with chemotherapy. The patient should discuss this and other options with their doctor prior to entering this study. Laboratory studies have demonstrated that ER is actually present in some triple negative breast cancers but is "silenced" (does not function properly) because methyl and histone groups are attached to it and inactivate it. Special drugs called demethylating inhibitors (such as decitabine) and histone deacetylase inhibitors (such as LBH589) can remove these methyl and histone groups and reactivate ER. This reactivated ER can then be targeted with agents like tamoxifen. The patient is being asked to join this clinical research study to find out if ER can be reactivated in their cancer using decitabine in combination with LBH589. If ER is reactivated in their cancer, we will then determine if tamoxifen can decrease the growth of the cancer.

Conditions

Breast Cancer; Breast Tumors; Breast Neoplasms

Keywords

Breast Cancer; Breast Tumors; Breast Neoplasms

Outcome Measures

Primary Outcomes (1)

• To Determine the Maximum Tolerated Dose of Decitabine and LBH589 Given in Combination in Patients With Metastatic or Locally Advanced Metastatic Breast Cancers

  Estrogen receptor status checked 5 days after treatment. Staging is done every 8 weeks.

Secondary Outcomes (1)

• To Determine the Safety of Tamoxifen in Combination With Decitabine and LBH589

  Patients will undergo an evaluation for extent of disease 8 weeks from starting study drugs and every 8 weeks (2 cycles) while on study.

Study Arms (1)

Arm A

EXPERIMENTAL

Patients treated with decitabine and LBH589

Drug: Decitabine, LBH589, Tamoxifen

Interventions

Decitabine, LBH589, Tamoxifen DRUG

Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2 Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2 Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2 Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2 Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2 Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2

Also known as: LBH589, Decitabine, Dacogen, Novaldex

Arm A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed triple negative (ER-, PR-, HER2-) metastatic or locally advanced breast cancer
• Measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• Disease that is assessable to biopsy for hormone receptor measurement
• At least one line of therapy prior to study entry (acceptable therapies include chemotherapy ± anti-angiogenic therapy). Other investigational therapies except DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors are allowed.
• Age \> 18 years
• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 (Appendix A)
• Adequate bone marrow as evidenced by:
• Absolute neutrophil count \> 1,500/μL
• Platelet count \> 100,000/μL
• Adequate renal function as evidenced by serum creatinine \< 1.5 mg/dL
• Adequate hepatic function as evidenced by:
• Serum total bilirubin \< 1.5 mg/dL
• Alkaline phosphatase \< 3 times the upper limit of normal (ULN) for the reference lab (\< 5 times the ULN for patients with known hepatic metastases
• Serum glutamic-oxaloacetic transaminase (SGOT)/serum glutamic-pyruvic transaminase (SGPT) \< 3 times the ULN for the reference lab (\< 5 times the ULN for patients with known hepatic metastases
• Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy or other antineoplastic therapy

You may not qualify if:

• Patients with an active infection or with a fever \> 101.30 F within 3 days of the first scheduled day of protocol treatment
• Patients with active central nervous system (CNS) metastases. Patients with stable CNS disease, who have undergone radiotherapy at least 4 weeks prior to the planned first protocol treatment and who have been on a stable dose of corticosteroids for \>3 weeks are eligible for the trial
• History of prior malignancy within the past 5 years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current prostate-specific antigen (PSA) of \< 1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry
• Patients with known hypersensitivity to any of the components of decitabine or LBH589
• Patients who received radiotherapy to more than 25% of their bone marrow; or patients who received any radiotherapy within 4 weeks of entry
• Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 28 days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
• Peripheral neuropathy \>= Grade 2
• Patients who are pregnant or lactating
• Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
• History of allogeneic transplant
• Known HIV or Hepatitis B or C (active, previously treated or both)

Sponsors & Collaborators

• Emory University: lead
• Novartis: collaborator
• Eisai Inc.: collaborator

Study Sites (1)

Emory University Winship Cancer Institute

Atlanta, Georgia, 30329, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Decitabine; Panobinostat; Tamoxifen

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Azacitidine; Aza Compounds; Organic Chemicals; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides; Hydroxamic Acids; Hydroxylamines; Amines; Hydroxy Acids; Carboxylic Acids; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons

Results Point of Contact

• Title: Ruth O'Regan, MD
• Organization: Emory University School of Medicine

roregan@emory.edu

404-778-4824

Study Officials

• Ruth O'Regan, MD

  Emory University Winship Cancer Institute

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Physician

Study Record Dates

• First Submitted: September 1, 2010
• First Posted: September 3, 2010
• Study Start: July 1, 2010
• Primary Completion: January 1, 2014
• Study Completion: January 1, 2014
• Last Updated: January 26, 2015
• Results First Posted: January 26, 2015

Record last verified: 2015-01

Locations

US (1)